The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema

To evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved with ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) for treatment of diabetic macular edema (DME) in the RIDE and RISE phase 3 studies. Exploratory, post hoc analysis of 2 randomized, double-m...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 123; no. 7; pp. 1581 - 1587
Main Authors:	Singh, Rishi P, Habbu, Karishma, Ehlers, Justis P, Lansang, M Cecilia, Hill, Lauren, Stoilov, Ivaylo
Format:	Journal Article
Language:	English
Published:	United States 01.07.2016
Subjects:	Adult Aged Angiogenesis Inhibitors - therapeutic use Biomarkers - blood Blood Glucose - analysis Blood Pressure - physiology Diabetic Retinopathy - blood Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Double-Blind Method Female Glycated Hemoglobin A - analysis Humans Intravitreal Injections Macular Edema - blood Macular Edema - drug therapy Macular Edema - physiopathology Male Middle Aged Ranibizumab - therapeutic use Visual Acuity - physiology
ISSN:	1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!